Drug releasing coatings for medical devices

• US 9,289,539 B2
• Filed: 04/10/2015
• Issued: 03/22/2016
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US14/683,612
• Publication Number:
  US 20150209489A1
• Time in Patent Office: 347 Days
• US Class Current: 1/1
• CPC Class Codes: A61F 2/844 folded prior to deployment
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00

Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Claims

1. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising:

a coating layer overlying an exterior surface of the medical device, wherein;

the coating layer consisting essentially of a therapeutic agent and at least one additive;

the therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;

the at least one additive is selected from the group consisting of urea, acetamide, lactic acid amide, aminoacid amide, acetaminophen, uric acid, polyurea, urethane, urea derivatives, niacinamide, N-methylacetamide, N,N-dimethylacetamide, sulfacetamide sodium, versetamide, lauric diethanolamide, lauric myristic diethanolamide, N,N-Bis(2-hydroxyethyl stearamide), cocamide EA, and cocamide DEA.

2. The medical device of claim 1, wherein the at least one additive is selected from the group consisting of urea, acetamide, aminoacid amide, uric acid, polyurea, N-methylacetamide, N,N-dimethylacetamide, sulfacetamide sodium, versetamide, lauric diethanolamide, lauric myristic diethanolamide, N,N-Bis(2-hydroxyethyl stearamide), cocamide EA, and cocamide DEA.

3. The medical device of claim 1, wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, a laser catheter, or a stent graft.

4. The medical device of claim 1, wherein the at least one additive is selected from the group consisting of urea, uric acid, polyurea, urethane, and urea derivatives.

5. The medical device of claim 1, wherein the at least one additive comprises urea.

6. The medical device of claim 5, wherein the medical device is a balloon catheter.

7. The medical device of claim 1, wherein the therapeutic agent comprises paclitaxel and the at least one additive comprises urea.

8. The medical device of claim 1, wherein the medical device is a balloon catheter, the therapeutic agent comprises paclitaxel, and the at least one additive comprises urea.

9. The medical device of claim 1, wherein the medical device is a stent graft, the therapeutic agent comprises paclitaxel, and the at least one additive comprises urea.

10. The medical device of claim 1, wherein the at least one additive does not react with the therapeutic agent during sterilization of the medical device.

11. The medical device of claim 1, wherein the at least one additive does not react with the therapeutic agent during sterilization of the medical device in ethylene oxide.

12. The medical device of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

13. The medical device of claim 1, wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.

14. The medical device of claim 1, further comprising a top layer overlying the surface of the coating layer overlying the exterior surface of the medical device to reduce loss of therapeutic agent during transit through a body to the tissue.